Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenomsBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7475.1129 (Published 11 November 2004) Cite this as: BMJ 2004;329:1129
- Roger Smalligan, hospital director1,
- Judy Cole1,
- Narcissa Brito, senior hospital technician1,
- Gavin D Laing, research scientist2,
- Bruce L Mertz, clinician1,
- Steven Manock, clinician1,
- Jeffrey Maudlin, clinician1,
- Brad Quist, clinician1,
- Gary Holland, clinician1,
- Stephen Nelson, clinician1,
- David G Lalloo, clinical senior lecturer2,
- Gonzalo Rivadeneira, doctor3,
- Maria Elena Barragan, herpetologist4,
- Daniel Dolley, human biology student5,
- Michael Eddleston, Wellcome Trust career development fellow5,
- David A Warrell (), professor of tropical medicine and infectious diseases5,
- R David G Theakston, professor of medical biology2
- 1 Hospital Vozandes del Oriente, Shell, Pastaza, Ecuador
- 2 Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool L3 5QA
- 3 Ministry of Health, Guayaquil, Ecuador
- 4 Fundacion Herpetologica Gustavo Orcés, Quito, Ecuador
- 5 Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU
- Correspondence to: D A Warrell
Objective To compare the efficacy and safety of three polyspecific antivenoms for bites by pit vipers.
Design Randomised double blind comparative trial of three antivenoms.
Setting Shell, Pastaza, southeastern Ecuador.
Participants 210 patients with incoagulable blood were recruited from 221 consecutive patients admitted with snake bite between January 1997 and December 2001.
Intervention One of three antivenoms manufactured in Brazil, Colombia, and Ecuador, chosen for their preclinical potency against Ecuadorian venoms.
Main outcome measures Permanent restoration of blood coagulability after 6 and 24 hours.
Results The snakes responsible for the bites were identified in 187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68 (36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or Lachesis muta. Eighty seven patients (41%) received Colombian antivenom, 82 (39%) received Brazilian antivenom, but only 41 (20%) received Ecuadorian antivenom because the supply was exhausted. Two patients died, and 10 developed local necrosis. All antivenoms achieved the primary end point of permanently restoring blood coagulability by 6 or 24 hours after the start of treatment in > 40% of patients. Colombian antivenom, however, was the most effective after initial doses of 20 ml (two vials), < 70 ml, and any initial dose at both 6 and 24 hours. An initial dose of 20 ml of Colombian antivenom permanently restored blood coagulability in 64% (46/72) of patients after 6 hours (P = 0.054 compared with the other two antivenoms) and an initial dose of < 70 ml was effective at 6 hours (65%, P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid reactions were common (53%, 73%, and 19%, respectively, for Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001) but only three reactions were severe and none was fatal.
Conclusions All three antivenoms can be recommended for the treatment of snakebites in this region, though the reactogenicity of Brazilian and Colombian antivenoms is a cause for concern.
Each year in Ecuador, 1200-1400 cases of snake bite are reported in 19 of the 21 provinces. Reports from Santo Domingo de los Colorados, Guayaquil,1 and Shell2 confirm its importance. In “El Oriente,” east of the Andes, the principal venomous species are Bothrops atrox (common lancehead) and B bilineatus smaragdinus (two striped forest pit viper, also known as Bothriopsis bilineata smaragdina). B taeniatus (speckled forest pit viper, also known as Bothriopsis taeniata), the less common Bothrops and Bothrocophias species and Lachesis muta (bushmaster) cause some bites.3 4 The indigenous Amerindian peoples and people of mixed European ethnicity, whose occupations include farming and logging, are all at risk of snake bite. The principal clinical effects of envenoming by B atrox are life threatening bleeding and blood coagulation disorders, shock, and renal failure. Necrosis and bacterial infection at the site of the bite may cause permanent physical handicap. Envenoming by B bilineatus is usually less severe. Other species such as B brazili and L muta, although potentially as dangerous as B atrox, rarely bite people.4
In an earlier preclinical laboratory study, the neutralising potency of five antivenoms (Brazilian, Ecuadorian, Mexican, and two Colombian) was tested against the venoms of B atrox, B asper, and B xanthogrammus.5 6 The Brazilian antivenom proved most effective, followed by the Ecuadorian and two Colombian antivenoms. The Mexican antivenom showed absolutely no neutralising activity against Ecuadorian Bothrops venoms, consistent with its poor clinical reputation in Ecuador.5 We selected the three most effective antivenoms for a double blind randomised comparative clinical trial in Ecuador.
The main lethal effect of the venoms of the crotaline (rattlesnake-like) pit vipers responsible for envenoming is intracranial or gastrointestinal haemorrhage resulting from vascular endothelial damage, platelet dysfunction, and consumption coagulopathy. These dangerous antihaemostatic disorders and their reversal by specific antivenoms are reflected by whole blood coagulability, which is easily assessed at the bedside with a simple but sensitive 20 minute whole blood clotting test.7 8 We therefore used this test to measure the efficacy of the three antivenoms in restoring whole blood coagulability and observed early reactions to assess safety.
During the five year period January 1997-January 2002, patients of any age who presented with a history of snake bite at any time during the day or night to Hospital Vozandes del Oriente, Shell, Pastaza, Ecuador, were considered for the study, unless they had received antivenom within the previous 6 hours. Patients were included if the result of the blood clotting test showed that their blood would not coagulate.7 8 Patients or their relatives gave informed consent for admission, investigation, and treatment. All patients were admitted to the hospital and kept under observation for at least 48 hours. History, physical examination, and other relevant details were recorded on standard proformas. All members of the medical team were involved in the study, providing 24 hour cover.
Antivenom treatment and randomisation
We randomised patients in blocks of six to treatment with one of three antivenoms5 9: Suero Antiofidico (Instituto Nacional de Higiene y Medicina Tropical “Leopoldo Izquieta Perez” Guayaquil, Ecuador); Soro Antibotropico (Instituto Butantan, San Paulo, Brazil); and Antiveneno Polivalente (Instituto Nacional de Salud, Bogota, Colombia).
The expiry dates of all the antivenoms used was December 2000 but from January 2001 until the end of the study, the Brazilian and Colombian antivenoms remained clear solutions and their in vivo neutralising potencies were undiminished.10 By this time the Ecuadorian antivenom had already run out (see below).
We calculated that we would need to recruit 100 patients to each arm to detect an increase from 50% to 73% in the proportion of patients with clotting blood at 6 hours (80% power). After the 140th patient, the supply of Ecuadorian antivenom ran out, but strict randomisation was maintained to either Brazilian or Colombian antivenom. Allocation was determined by a table of random numbers. The antivenoms were packaged in numbered envelopes. The nurse on duty was responsible for drawing up the antivenoms, all indistinguishable colourless solutions, into an unmarked syringe so that the medical staff treating and assessing the patient and the patient were effectively blinded.
Most patients received an initial dose of 20 ml (two vials) of antivenom by intravenous injection over 10 minutes. A minority, considered on admission to be severely envenomed, were given higher initial doses of up to 70 ml (seven vials). Six hours after the start of antivenom treatment, we checked blood coagulability using the 20 minute clotting test. If the blood was still not coagulable, we administered a second dose of 20 ml of antivenom. Further doses were given at every six hours until blood coagulability was restored permanently.
All medical staff responsible for administering antivenom were familiar with the signs of early anaphylactoid reactions and watched the patients carefully for such signs. These were treated with subcutaneous adrenaline (epinephrine) and intravenous diphenhydramine and hydrocortisone, as was the current practice in Ecuador at the time of the study. Pain was treated with oral paracetamol, intravenous pethidine, or tramadol. Patients received fresh compatible HIV negative blood if their packed cell volume fell below 20%, and routine tetanus prophylaxis was given. Local necrosis was treated by immediate surgical debridement, gentamicin, and chloramphenicol.
Snakes responsible for the bites
Dead snakes brought to the hospital were labelled and preserved in 10% formalin or 70% ethanol. They were formally identified at the Fundacion Herpetologica Gustavo Orcés in Quito.
Venous blood was sampled on admission, at 6, 12, 18, and 24 hours later, and then daily until patients were discharged from hospital. Blood coagulability was determined by the 20 minute clotting test. We obtained background levels of absorbance in the enzyme immunoassay from blood samples taken from 100 relatives or friends of patients who had not been bitten in the past and were considered representative of the normal population within the study area.11 We froze residual plasma/serum from the blood clotting test for detection of specific venom antigen by enzyme immunoassay using the technique described by Ariaratnam et al12 but with an additional step before the wells were coated with antiserum. Four millilitres of each antiserum was passed over a CN-Br activated Sepharose 4B affinity column (Sigma, Poole, Dorset) to which was bound 5 mg of each venom to retain as much venom specific antibody as possible. Enzyme immunoassays were developed for five different venoms (B atrox, B bilineatus smaragdinus, B taeniatus, B brazili, and L muta). This assay had been validated in a separate study by testing admission samples from 57 patients selected because all had brought in the dead snake (personal communication). Therapeutic antivenom concentrations were measured by enzyme immunoassay in 103 patients.11
We constructed a database using Microsoft Access and compared the efficacy of antivenoms and reaction rates with 2x3 tables. The relation between the dose of antivenom required and the initial serum concentration of venom antigen was determined with the Kruskal-Wallis test.
Randomisation and clinical features
We recruited 210 patients with incoagulable blood (fig 1). Eighty seven patients (41.4%) received Colombian INS antivenom, 82 (39%) received Brazilian antivenom, but only 41 (19.5%) received Ecuadorian antivenom because the supply ran out after the 140th patient (table 1). The groups of patients receiving the three different antivenoms were similar in all respects on admission to hospital and before they received treatment (tables 1 and 2). Table 2 shows the clinical features of recruited patients.
Snakes responsible for bites
Twenty nine patients (14%) brought in the snake responsible for the bite: 13 (45%) were identified as B atrox, 12 (41%) as B bilineatus smaragdinus, 2 (7%) as B taeniatus, and 2 (7%) remained unidentified (table 1). Specimens of B atrox ranged from 20-90 cm (mean 43 cm, SD 22 cm) and B bilineatus 15-50 cm (34 cm, SD 14 cm) and the two B taeniatus specimens measured 150 cm and 180 cm. With the help of herpetologists and the results of enzyme immunoassay we identified the snake responsible for envenoming in 187 (89%) cases: 109 (58%) were bitten by B atrox, 68 (36%) by B bilineatus, 6 (3%) by B taeniatus, 1 (1%) by B brazili, and 3 (2%) by L muta. The distribution of bites by the different species was similar among the three groups (table 1).
Venom antigen detection
We assessed the serum concentrations of venom antigen from admission to discharge in 148 patients out of the 180 who received an initial dose of 20 ml of antivenom (samples from 32 patients were lost during transport from Shell to Quito). Concentrations on admission correlated significantly with the total volume of antivenom required to restore blood coagulability permanently (P < 0.0001). In the small group of patients who required more than 60 ml of antivenom, median venom antigen concentrations were about fourfold to fivefold higher than those in patients who required only 20 ml of antivenom (fig 2). The time to venom clearance was also longer in patients who required higher doses of antivenom (fig 3).
Efficacy of antivenom treatment
Two patients died. A 4 year old boy treated with Brazilian antivenom and a 38 year old woman treated with Colombian antivenom died 11 hours and 3 days, respectively, after being bitten by B atrox. Both developed acute pulmonary oedema from which they could not be resuscitated. Ten patients (5% in each treatment group) developed local necrosis. All other patients were well on discharge from hospital.
Table 3 gives details of the comparative efficacy of the antivenoms. One hundred and eighty patients were treated with an initial dose of 20 ml (two vials). In those who received this dose of Colombian antivenom, blood coagulability was restored in 64% (46/72) at 6 hours compared with 49% (35/72) and 42% (15/36) of those who received Brazilian and Ecuadorian antivenoms, respectively (P = 0.054). Permanent restoration of coagulability was recorded within 24 hours after starting treatment in almost all patients given 20 ml of Colombian antivenom (64/65; 99%), in 60/67 (90%) treated with the Brazilian antivenom, and in 32/35 (91%) treated with the Ecuadorian antivenom. Colombian antivenom also proved superior when the initial dose was < 70 ml and after any initial dose of antivenom (table 3). Eighty one patients (45%) required more than one dose of antivenom, including 11 patients whose blood became incoagulable again after a normal result from the whole blood clotting test at 6 hours. There was no difference in median total doses of the three antivenoms.
Therapeutic concentrations of antivenom
Of the 103 patients in whom we measured serum concentrations of therapeutic antivenom, 63 had received an initial dose of 20 ml with or without subsequent doses. Antivenom was detectable in the serum when serum venom antigenaemia had become undetectable and for at least 48 hours, even in those who had received only a single dose of antivenom (fig 4).
Early reactions to antivenom were common, including rash, vomiting, abdominal pain, fevers and chills, pruritis, and, more seriously, dyspnoea and hypotension. In those receiving an initial antivenom dose of 20 ml, reaction rates were 19% (7/37) in those receiving Ecuadorian antivenom, 73% (56/71) for Colombian, and 53% (37/70) for Brazilian antivenom. These rates were significantly different from each other (P < 0.0001). Two patients who developed hypotension had been treated with Colombian antivenom, one with Brazilian antivenom, and one with Ecuadorian antivenom.
In this randomised double blind comparative trial of three polyspecific antivenoms in 210 patients with venom induced coagulopathy, the resolution of coagulopathy at 6 and 24 hours after the initial dose were the primary end points. We chose the 6 hour time interval because of the frequently reported observation that, in envenomed patients, blood coagulability is usually restored within 3-6 hours of the administration of a dose of antivenom sufficient to neutralise circulating procoagulant toxins.13–18 If an initial two vials (20 ml) of antivenom failed to correct the coagulopathy within 6 hours, a further two vials were given. Judged by this criterion, Colombian antivenom proved the most effective.
We could not detect any difference in the ability of the three antivenoms to eliminate or reduce local effects of envenoming. Only 10 patients (5%) developed local necrosis, the main cause of persistent morbidity in those who survive severe envenoming. The pathophysiology of local envenoming may involve direct and indirect inflammatory mechanisms that are independent of neutralisation of venom toxins mediated through antivenom.19–22
The high incidence of symptoms of early anaphylactoid reactions (including rash, vomiting, abdominal pains, fevers, chills, pruritis, dypnoea, and hypotension) in our patients was reminiscent of results of a study in Brazil in which reaction rates as high as 84% were recorded.13 In other studies, early reaction rates ranged from 3% to 54%.23–25 Among 178 patients who could be closely monitored, 100 (56%) suffered early reactions. The antivenoms differed significantly in their rates of reaction (Ecuadorian 19%, Brazilian 53%, Colombian 73%, P < 0.0001). The higher reactogenicity of Colombian antivenom may reflect its higher protein content (61 mg/ml) compared with the two other antivenoms (Ecuadorian 47 mg/ml, Brazilian 44 mg/ml)5 and the fact that it is a whole IgG ammonium sulphate precipitated preparation, whereas the other two antivenoms are pepsin digested F(a)2 fragments.5 Severe reactions were rare and were promptly reversed by use of adrenaline, antihistamines, and corticosteroids.
Enzyme immunoassay was useful for identifying the snake responsible for envenoming. Concentrations of venom antigen on admission correlated with the severity of envenoming, as in studies of envenoming by Vipera aspis,26 B lanceolatus,27 and Daboia siamensis.28 Patients whose venom antigenaemia was relatively low required treatment with only two vials (20 ml) of antivenom, whereas those with higher levels needed repeated doses of antivenom. Venom clearance by antivenom occurred more rapidly in patients with lower venom antigenaemias on admission, as in patients bitten by B jararaca.29
B atrox and B bilineatus smaragdinus are responsible for most snake bites in the Pastaza region. B atrox is notorious as the leading cause of severe snake bites wherever it occurs in South America.4 16 In contrast, B bilineatus, a distinctive bright green arboreal snake, is less well known as a snake of real medical importance.30 In this study 36% of our patients were bitten by this species and 6% by B taeniatus, B brazili, and L muta. Other crotalines including B pulcher (formerly B albocarinatus and also known as Bothriopsis pulchra), Bothrocophias (formerly Bothrops and Porthidium) hyoprora, and Bothrocophias microphthalmus are known to inhabit this area of unusual diversity of venomous snakes.4
All three of the tested antivenoms were clinically adequate in eastern Ecuador. Colombian antivenom, however, was the most effective judged by speed and efficiency in permanently correcting venom induced coagulopathy. The Ecuadorian antivenom was significantly less likely than either of the other two antivenoms to cause early anaphylactoid reactions. We recommended that the Ecuadorian Ministry of Health should increase production of this antivenom or, failing that, import either Colombian or Brazilian antivenoms to improve the treatment of snake bite envenoming in the Ecuadorian Amazon region.
What is already known on this topic
Most studies on effectiveness of antivenom in snake bite have been carried out by estimating neutralising potency in experimental animals
Few well designed clinical trials have been carried out on the treatment of human snake bite in the rural tropics
What this study adds
A simple, accurate, and robust whole blood clotting test can be used to assess the ability of three antivenoms (Brazilian, Colombian, and Ecuadorian) to eliminate venom induced coagulopathy permanently
Enzyme immunoassay enabled the accurate identification of the snake species responsible for envenoming
Although the Colombian antivenom proved the most effective, all three antivenoms proved suitable for treating snakebite victims in this region
The Brazilian and Colombian antivenoms caused a high incidence of anaphylactoid reactions. This should prompt their manufacturers to improve production procedures
We thank the staff (medical, administrative, nursing, and technical) of Hospital Vozandes del Oriente, Shell, Pastaza; I Hastings (statistical advice) and A Richards (technical help), Liverpool School of Tropical Medicine; and the Ecuadorian Ministry of Health. We thank Philip Cooper, Hospital Vozandes, Quito, who arranged the transport of specimens from Ecuador to Liverpool.
Contributors DAW and RDGT conceived, planned, and wrote up the study with help from SM, ME, and DGL. RS, JC, BLM, SM, JM, BQ, GH, and SN contributed to the design of the study, treated the patients, and collected appropriate samples. NB organised the collection and labelling of the samples, and GDL performed the immunoassays. ME designed the database, and DGL extracted the data and performed the statistical calculations. MEB was responsible, with DAW, for the identification of the snakes and with DAW and RDGT for obtaining the venom used for EIA studies. DD, working in Shell hospital, collected data from the patients' records. GR was responsible for coordination of the project with the Ecuadorian Ministry of Health. DAW is guarantor.
Funding European Union (contract No ERBIC18-CT96-0032). The Instituto Butantan (San Paulo, Brazil), the Instituto Nacional de Salud (Bogota, Colombia), and the Instituto Nacional de Higiene y Medicina Tropical (Guayaquil, Ecuador) donated the antivenoms.
Competing interest None declared.
Ethical approval Ecuadorian Ministry of Health and Hospital Vozandes del Oriente, Shell, Pastaza, Ecuador.